BioWorld Asia

Feb. 7, 2007

Push By AstraZeneca Includes COPD Deal Worth Up To $500M

LONDON - AstraZeneca plc went through a hyperactive round last week of licensing and acquisitions, sealing deals worth $650 million. (BioWorld International) Read More

Circassia Raises £6M To Move Its Allergenic Products Ahead

Study Confirms Prion Protein As Therapeutic Target In CJD

ScanBalt Promoting Baltic Biotechnology Cooperation

AstraZeneca Buys Antiviral Firm Arrow For $150M Cash

Jerini Extends Pact With Baxter For New Hemophilia Drugs

NicOx Details Offer To Raise €130M

No Abstract Read More

Europe Moves Ahead On Advanced Therapy Rules

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 10, 2026.

Microscopic image of clear cell carcinoma, the most common type of renal cell carcinoma.

Cas and effect: Merck’s phase III ripples HIF-2α space

BioWorld

Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...

Tanycytes in green capturing tau protein in red.

Brain’s hidden tau-clearing pathway uncovered

BioWorld Science

Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

MSD synthesizes α-synuclein PET agents

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...